Alain Chapel
Institute of Radioprotection and Nuclear Safety, France
Biography
For 20 years, he has been developing gene and cell therapy to protect against the side effects of radiation. He collaborates with clinicians to develop new strategies for treatment of patients after radiotherapy overexposures. He has participated in the first establishment of proof of concept of the therapeutic efficacy of Mesenchymal stem cells (MSCs). Currently his work focuses on the development of radio-induced bone marrow aplasia using human hematopoietic stem cells derived from human IPS. He is a member of various learned national and international societies and associate editor of international journals. Hirsch Index 22.
Abstract
Abstract : Stem cell therapy for the treatment of severe tissue damage after radiation exposure